Stockscreener 앱 받기
204.80
2.16%
4.33
시간 외 거래:
204.80
전일 마감가:
$200.47
열려 있는:
$202.81
하루 거래량:
1.24M
Relative Volume:
0.32
시가총액:
$317.61B
수익:
$58.80B
순이익/손실:
$10.24B
주가수익비율:
62.46
EPS:
3.2788
순현금흐름:
$8.98B
1주 성능:
+0.38%
1개월 성능:
+7.06%
6개월 성능:
+141.82%
1년 성능:
+203.00%
1일 변동 폭
$202.55
$205.30
1주일 범위
$199.50
$205.30
52주 변동 폭
$66.16
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
204.80 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
927.03 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.18 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
208.38 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.07 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained U.S. in - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca’s Danicopan Korea Study: Real-World Data That Could Shape AZN’s Rare Disease Edge - TipRanks
Mirae Asset Global Investments Co. Ltd. Acquires 42,665 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
AstraZeneca stock holds steady after Assetmark Inc. and Pursuit Wealth buy shares - Traders Union
Astrazeneca Plc $AZN Shares Sold by Iams Wealth Management LLC - MarketBeat
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by Pr - GuruFocus
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
AstraZeneca (AZN) Advances Portfolio with Strategic Update - GuruFocus
AstraZeneca (AZN) Faces Rising Drug Prices Amid Senate Scrutiny - GuruFocus
Pursuit Wealth Management LLC Takes Position in Astrazeneca Plc $AZN - MarketBeat
Assetmark Inc. Buys 25,004 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Australia
AstraZeneca stock holds steady after $191 million grant for Albemarle facility approved - Traders Union
ZWJ Investment Counsel Inc. Lowers Holdings in Astrazeneca Plc $AZN - MarketBeat
Bingham Private Wealth LLC Takes $669,000 Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): Why does its oncology dominance matter more now for U.S. inves - AD HOC NEWS
AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study - TipRanks
AstraZeneca plc stock (GB0009895292): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
32,091 Shares in Astrazeneca Plc $AZN Bought by Third View Private Wealth LLC - MarketBeat
AstraZeneca Adds to Demands on Hospitals Seeking Drug Discounts - Bloomberg Law News
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
Yousif Capital Management LLC Decreases Stake in Astrazeneca Plc $AZN - MarketBeat
Hardman Johnston Global Advisors LLC Reduces Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca India to divest Bengaluru manufacturing site for INR 3,400 crore - Prop News Time
Astrazeneca Plc $AZN Shares Bought by Apollon Wealth Management LLC - MarketBeat
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - Yahoo Finance
Is AstraZeneca Still in Focus After Strong Market Momentum? - Kalkine Media
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM - The Globe and Mail
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside - Yahoo Finance UK
AstraZeneca India Expands Cancer Drug Use, Stock Gains on Approval - Whalesbook
ASTRAZENECA : UBS gives a Buy rating - marketscreener.com
ASTRAZENECA : Jefferies reaffirms its Buy rating - marketscreener.com
PDL1 Antibody Reagent Market is Going to Boom: AstraZeneca • Pfizer • Novartis • Abcam - openPR.com
AstraZeneca shareholders approve all resolutions at annual general meeting - Investing.com
AstraZeneca shareholders approve all resolutions at annual general meeting By Investing.com - Investing.com UK
AstraZeneca (AZN) shareholders back all AGM resolutions and buyback - Stock Titan
AstraZeneca Triumphs at AGM: All Resolutions Passed - Devdiscourse
AstraZeneca announces all AGM resolutions including Special Resolutions 10-13 passed - marketscreener.com
AstraZeneca, Sun Dismiss Patent Suits Over Three Diabetes Drugs - Bloomberg Law News
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com India
Erste Group Bank Comments on Astrazeneca FY2026 Earnings - MarketBeat
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 2026 - Meyka
AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit - Law360
AstraZeneca (NYSE: AZN) delists 0.700% Notes due 2026 from NYSE - Stock Titan
AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study - TipRanks
AstraZeneca : Sustainability Data Reporting Criteria 2025 - marketscreener.com
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.13%
0.29%
자본화:
|
볼륨(24시간):